vimarsana.com

Page 11 - Pascal Deschatelets News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stifel Nicolaus Increases Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $65 00

Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report) had its price target boosted by investment analysts at Stifel Nicolaus from $60.00 to $65.00 in a research report issued on Tuesday, MarketBeat reports. The brokerage currently has a “buy” rating on the stock. Stifel Nicolaus’ price target would suggest a potential upside of 60.06% from the company’s […]

Apellis Pharmaceuticals (NASDAQ:APLS) PT Raised to $54 00

Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report) had its price objective raised by research analysts at Citigroup from $45.00 to $54.00 in a note issued to investors on Tuesday, MarketBeat reports. The firm currently has a “buy” rating on the stock. Citigroup’s price target suggests a potential upside of 32.97% from the company’s current price. […]

Nicholas Investment Partners LP Grows Position in Apellis Pharmaceuticals, Inc (NASDAQ:APLS)

Nicholas Investment Partners LP raised its stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 35.7% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 336,951 shares of the company’s stock after purchasing an additional 88,668 shares during the period. Apellis Pharmaceuticals […]

Apellis Pharmaceuticals (NASDAQ:APLS) Earns Buy Rating from Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) in a research note issued to investors on Thursday, Benzinga reports. They currently have a $60.00 price objective on the stock. A number of other analysts have also commented on APLS. Oppenheimer reissued an outperform rating on shares […]

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.